Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein: revealing the critical antigenic determinants in inactivated SARS-CoV vaccine. (Q52571074)

From Wikidata

Jump to navigation Jump to search

scientific article published on 11 May 2006

Language	Label	Description	Also known as
English	Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein: revealing the critical antigenic determinants in inactivated SARS-CoV vaccine.	scientific article published on 11 May 2006

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/16725238

Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein: revealing the critical antigenic determinants in inactivated SARS-CoV vaccine. (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/16725238

0 references

1 reference

based on heuristic

inferred from title

7

object named as

Shibo Jiang

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/16725238

3

object named as

Lanying Du

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/16725238

6

object named as

Yusen Zhou

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/16725238

author name string

Yuxian He

1

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/16725238

Jingjing Li

2

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/16725238

Xuxia Yan

4

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/16725238

Guangan Hu

5

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/16725238

language of work or name

0 references

publication date

11 May 2006

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/16725238

number of pages

11

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/16725238

24

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/16725238

26

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/16725238

5498-5508

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/16725238

Identification of a novel coronavirus in patients with severe acute respiratory syndrome

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.04.054

7 January 2021

A novel coronavirus associated with severe acute respiratory syndrome

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.04.054

7 January 2021

The Genome sequence of the SARS-associated coronavirus

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.04.054

7 January 2021

Coronavirus as a possible cause of severe acute respiratory syndrome

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.04.054

7 January 2021

Characterization of a novel coronavirus associated with severe acute respiratory syndrome

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.04.054

7 January 2021

Virus detectives seek source of SARS in China's wild animals

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.04.054

7 January 2021

Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.04.054

7 January 2021

Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.04.054

7 January 2021

Bats are natural reservoirs of SARS-like coronaviruses

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.04.054

7 January 2021

Vaccine design for severe acute respiratory syndrome coronavirus

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.04.054

7 January 2021

SARS vaccine development

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.04.054

7 January 2021

Medicine. Caution urged on SARS vaccines

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.04.054

7 January 2021

A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.04.054

7 January 2021

Inactivated SARS-CoV vaccine prepared from whole virus induces a high level of neutralizing antibodies in BALB/c mice

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.04.054

7 January 2021

Immunogenicity of SARS inactivated vaccine in BALB/c mice

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.04.054

7 January 2021

Immune responses in Balb/c mice induced by a candidate SARS-CoV inactivated vaccine prepared from F69 strain

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.04.054

7 January 2021

Immunogenicity, safety, and protective efficacy of an inactivated SARS-associated coronavirus vaccine in rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.04.054

7 January 2021

Augmentation of immune responses to SARS coronavirus by a combination of DNA and whole killed virus vaccines

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.04.054

7 January 2021

Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.04.054

7 January 2021

Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.04.054

7 January 2021

Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS.

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.04.054

7 January 2021

Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region.

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.04.054

7 January 2021

A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.04.054

7 January 2021

The secret life of ACE2 as a receptor for the SARS virus

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.04.054

7 January 2021

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.04.054

7 January 2021

A model of the ACE2 structure and function as a SARS-CoV receptor.

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.04.054

7 January 2021

Amino acids 270 to 510 of the severe acute respiratory syndrome coronavirus spike protein are required for interaction with receptor

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.04.054

7 January 2021

A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.04.054

7 January 2021

The SARS-CoV S glycoprotein: expression and functional characterization

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.04.054

7 January 2021

Identification of immunodominant sites on the spike protein of severe acute respiratory syndrome (SARS) coronavirus: implication for developing SARS diagnostics and vaccines

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.04.054

7 January 2021

Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.04.054

7 January 2021

An exposed domain in the severe acute respiratory syndrome coronavirus spike protein induces neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.04.054

7 January 2021

Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.04.054

7 January 2021

Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.04.054

7 January 2021

A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.04.054

7 January 2021

Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.04.054

7 January 2021

Structure of SARS coronavirus spike receptor-binding domain complexed with receptor

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.04.054

7 January 2021

Identification of two critical amino acid residues of the severe acute respiratory syndrome coronavirus spike protein for its variation in zoonotic tropism transition via a double substitution strategy.

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.04.054

7 January 2021

Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2.

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.04.054

7 January 2021

Single amino acid substitutions in the severe acute respiratory syndrome coronavirus spike glycoprotein determine viral entry and immunogenicity of a major neutralizing domain.

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.04.054

7 January 2021

The SARS coronavirus S glycoprotein receptor binding domain: fine mapping and functional characterization

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2006.04.054

7 January 2021

Immunogenicity and protective efficacy in monkeys of purified inactivated Vero-cell SARS vaccine

1 reference

https://pubmed.ncbi.nlm.nih.gov/16725238

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.VACCINE.2006.04.054

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/16725238

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/16725238

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q52571074&oldid=1775336380"